Showing 8651-8660 of 9366 results for "".
- ISD Survey: Climate Change Is A Real Threat to Skin Healthhttps://practicaldermatology.com/news/isd-survey-climate-change-is-a-real-threat-to-skin-health/2460451/The vast majority of dermatologists (95.6 percent) believe climate change is occurring and 88.6 percent indicated that climate change will impact the incidence of skin diseases in their areas, according to an online survey was conducted by the International Society of Dermatology's (ISD)
- Bimekizumab Phase 3 Data Show Superior Skin Clearance in Psoriasis vs. Placebo and Ustekinumabhttps://practicaldermatology.com/news/bimekizumab-phase-3-data-show-superior-skin-clearance-in-moderate-to-severe-psoriasis/2460421/UCB shared first presentations of data from the Phase 3 clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting. Patients treated with bimekizumab achieved superior
- ProTransit to Target Photodamage in Trials of New Nanoparticle Technologyhttps://practicaldermatology.com/news/protransit-to-target-photodamage-in-trials-of-new-nanoparticle-technology/2460418/ProTransit Nanotherapy plans to launch human clinical trials this summer with products that could target precursors of skin cancers. The company has developed therapies based nanoparticle technology invented at the University of Nebraska Medical Center to help prevent and potentially improve suns
- Tremfya Shows Improvement in PsA Joint and Skin Symptomshttps://practicaldermatology.com/news/tremfya-shows-improvement-in-psa-joint-and-skin-symptoms/2460412/Tremfya (guselkumab) demonstrated improvements in multiple clinical outcomes including joint symptoms, skin symptoms, soft tissue inflammation, physical function and reduction in radiographic progression at week 52 in adult patients with active psoriatic arthritis (PsA), according to data fr
- Promising Data from Dermavant's Phase 2b Study of Tapinarof in Psoriasishttps://practicaldermatology.com/news/promising-data-from-dermavants-phase-2b-study-of-tapinorof-in-psoriasis/2460405/Patients treated with once daily tapinarof 1% demonstrated improvement in PASI75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase
- Sunscreen Tips: Expert Shares Insights on Patient Educationhttps://practicaldermatology.com/news/sunscreen-tips-expert-shares-insights-on-patient-education/2460400/By Naz Saedi, MD A recent survey from the American Academy of Dermatology shows that 76 percent of people think that sunscreen is important but only about 40 percent wear sunscreen. These numbers indicate a significant disconnect; while people understand the concept and the importance o
- NRS Roundtable: Greater Focus on Facial Erythema in Rosacea Warrantedhttps://practicaldermatology.com/news/nrs-roundtable-greater-focus-on-facial-erythema-in-rosacea-warrated/2460392/Dermatologists should place greater emphasis on addressing persistent facial erythema in roscaea, according to experts at a recent National Rosacea Society (NRS) roundtable. Drawing from current scientific knowledge as well as clinical experience, the new standard classification of rosa
- Cabaletta Bio Receives FDA Fast Track Designation for DSG3-CAART for the Treatment of mPVhttps://practicaldermatology.com/news/cabaletta-bio-receives-fda-fast-track-designation-for-dsg3-caart-for-the-treatment-of-mpv/2460383/The U.S. Food and Drug Administration (FDA) granted Cabaletta Bio’s DSG3-CAART (Desmoglein 3 Chimeric AutoAntibody Receptor T cells) Fast Track Designation for improving healing of mucosal blisters in patients with mPV. DSG3-CAART is designed to specifically target the cause of mP
- COVID-19 By the Numbers: May 5 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-may-5-edition/2460375/Sixteen states have significantly reduced COVID-19 restrictions, while 18 have somewhat reduced restrictions, a new analysis from WalletHub reveals. The easing comes as the US reports nearly 70,000 COVI
- Suneva to Distribute Sinclair Pharma's Silhouette Instalift Sutureshttps://practicaldermatology.com/news/suneva-to-distribute-sinclair-pharmas-silhouette-instalift-sutures/2460372/Suneva Medical, Inc. is the exclusive North American distributor for Sinclair Pharma's Silhouette Instalift sutures "We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio,"